ScholarLens Back to search
2016•Formulary ENewsRequires access

6 facts to know about the new psoriasis drug

Christine Blank

Open publisher page 0 citations

Abstract

FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

About this research paper

What this paper is about

FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Key concepts: Psoriasis, Drug, Medicine, Computer science, Dermatology, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
6 facts to know about the new psoriasis drug — Research Paper | ScholarLens